Aktis Oncology (NASDAQ:AKTS) Trading 8.8% Higher – Time to Buy?

Aktis Oncology (NASDAQ:AKTS) rose 8.8% on Tuesday . The company traded as high as $33.15 and last traded at $32.7560. 134,837 shares changed hands during trading, a decline of 58% from the average daily volume of 322,742 shares. The stock had previously closed at $30.11.

Analyst Upgrades and Downgrades

AKTS has been the topic of a number of recent research reports. William Blair initiated coverage on Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating on the stock. Raymond James Financial began coverage on Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target for the company. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Finally, HC Wainwright raised their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Aktis Oncology Stock Performance

The firm has a 50-day moving average price of $21.12.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million during the quarter. Research analysts expect that Aktis Oncology will post -1.62 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.